Observational studies and the natural history of screen-detected prostate cancer

Current Opinion in Urology

Volumn 25, Issue 3, 2015, Pages 232-237

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

active surveillance; clinical outcomes; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; FOLLOW UP; GENETIC MARKER; HISTORY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; BLOOD; DISEASE COURSE; EARLY CANCER DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; MALE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; WATCHFUL WAITING;

DISEASE PROGRESSION; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM GRADING; OBSERVATIONAL STUDIES AS TOPIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 84928546870     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000157     Document Type: Review

References (20)

1. Young HH. Early diagnosis and radical cure of carcinoma of the prostate. Bull Johns Hopkins Hosp 1905; 16:314-321.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. Ca Cancer J Clin 2014; 64:9-29.
3. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379-385.
4. Albertsen PC, Hanley JA, Fine J. 20 year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293:2095-2101.
5. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of prostatic carcinoma. Am J Surg Path 2005; 29:1228-1242.
6. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97:1248-1253.
7. Draisma G, Boer R, Otto SJ, et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95:868-878.
8. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302:1202-1209.
9. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203-213.
10. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370:932-942.
11. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, et al. Prevalence of prostate cancer among men with a prostate specific antigen level 4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
12. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319.
13. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384:2027-2035.
14. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:120-144.
15. Gleason DF; Mellinger GT for the Veterans Administration Cooperative Urological Research Group. Predication of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974; 111:58-64.
16. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013; 111:753-760.
17. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, et al. Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 2012; 62:976-983.
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-374.
19. Lee DJ, Ahmed HU, Moore CM, et al. Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. Curr Urol Rep 2014; 15:390-400.
20. Ross AE, Loeb S, Landis P, Partin AW, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28:2810-2816.